The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster +68 more
wiley +1 more source
Esophageal myotomy and risk of esophageal cancer and mortality in achalasia: Real-world cohort study. [PDF]
Jaber F +8 more
europepmc +1 more source
Stratigraphies: The Long Poem of Place
This article examines the contemporary long poem of place, beginning with the author's own work 'The Hill' and exploring what drives contemporary poets to work in long form when writing about place.
openaire
al-Khansā’’s poem in -ālahā and its Qur’ānic echoes. The long and the short of it
Jaakko Hämeen‐Anttila
openalex +2 more sources
Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger +11 more
wiley +1 more source
Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique. [PDF]
Hao XW +8 more
europepmc +1 more source
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan [PDF]
Chika Kawajiri‐Manako +17 more
openalex +1 more source
Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham +14 more
wiley +1 more source
Severe Diabetic Gastroparesis and Complex Discharge Planning: Home IV Cyclizine As the Only Solution. [PDF]
Karim H, Ibrahimli A, Ikuesan T.
europepmc +1 more source

